Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

PHRMA

Filed by FORBES-TATE.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-21 06:26:11 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
$80,000.00
Expenses
Not reported
Registrant
FORBES-TATE
Client
PHRMA
Filing UUID
49f27d4b-5f28-47d6-a9b1-44abceedd46f
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

CSP · Consumer Issues/Safety/Products

Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

TRD · Trade (domestic/foreign)

Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

HCR · Health Issues

Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.

MMM · Medicare/Medicaid

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.